BioSenic SA is a biotechnology company with extensive scientific and clinical experience in the field of orthopedics and regenerative therapies, specializing in the clinical development of therapies for bone and cartilage repair. BioSenic SA still holds stakes in its clinical assets ALLOB and JTA, but is now focusing on joint development with 4Moving Biotech of a GLP-1-based disease-modifying therapy for veterinary use, particularly for recovery after ligament surgery in dogs. BioSenic SA is also focusing on other potential new partnerships.

Employees

Sector

Pharmaceuticals

More about the company

28/10/25	BioSenic S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
03/10/25	BioSenic S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

Market Cap	1.5M 1.72M 1.72M 1.39M 1.28M 2.43M 164M 2.47M 16.55M 6.5M 80.66M 6.45M 6.31M 277M	P/E 2023	-0.29x	P/E 2024	-0.28x
Enterprise Value	28.84M 32.97M 32.97M 26.6M 24.57M 46.61M 3.14B 47.4M 318M 125M 1.55B 124M 121M 5.33B	EV / Sales 2023	113x	EV / Sales 2024	286x
Free-Float	85.86%	Yield 2023 *	-	Yield 2024	-

28/10/25	BioSenic S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
03/10/25	BioSenic S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
29/09/25	Bone Therapeutics SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
28/10/24	BioSenic S.A. Announces Executive Changes	CI
30/09/24	BioSenic S.A. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
30/09/24	Bone Therapeutics SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
17/09/24	BioSenic Deputy CEO Steps Down	MT
17/09/24	Véronique Pomi-Schneiter Step Down as BioSenic's Deputy CEO	CI
14/08/24	BioSenic Unit Secures European Patent for Multiple Sclerosis Treatment	MT
14/08/24	Medsenic, Subsidiary of Biosenic Receives the Intention to Grant Key European Patent from European Patent Office	CI
13/08/24	BioSenic Grants of A Key Patent by the Japan Patent Office to Expand Protection of the Arsenic Trioxide Platform	CI
18/07/24	Biosenic Releases New In-Depth Analysis of Its Positive Phase 2 Clinical Data for Optimal Administration Scheme for Its Next Late-Stage Trial of Arsenic Trioxide Targeting Cgvhd	CI
05/07/24	BioSenic Seeks US Patent Extension for Sepsis Drug	MT

12-14	BioSenic : Report from Auditor on ESEF format 2024 Annual Report	PU
25/09/25	BioSenic : appoints CarKath SRL, represented by Mr Eric Halioua, as chairman of the board of directors	PU
29/08/25	BioSenic : provides an update on the preparation of the annual accounts and annual report for the financial year ending on 31 December 2024	PU
05/08/25	BioSenic : announces the homologation by the Enterprise Court of BioSenic's amicable agreements with five main creditors to restructure over €22 million of debt and appointment of two new independent directors	PU
01/07/25	BioSenic : announces partnership with 4Moving Biotech and secures its financing.	PU

05-07	BioSenic : Procuration pour l'actionnaire
05-07	BioSenic : Rapport annuel 2025
05-07	BioSenic : Communiqué de Presse - Convocation à l'Assemblée Générale Ordinaire
04-28	BioSenic : BIOS PR 2026 avril Denominator FR20260428
04-12	BioSenic : annonce l'émission de droits de souscription au bénéfice de membres du conseil d'administration

Bone Therapeutics SA Stock Euronext Bruxelles

Stocks

BOTHE

BE0974280126

Pharmaceuticals

Valuation: Bone Therapeutics SA

Latest news : Bone Therapeutics SA

Analysts' recommendations: Bone Therapeutics SA

Press Releases: Bone Therapeutics SA

News in other languages: Bone Therapeutics SA

Managers and Directors: Bone Therapeutics SA

Other Pharmaceuticals

Financials

Company Profile

Director	Title	Age	Since
Jean-Luc Vandebroek BRD	Director/Board Member	55	01/01/2022
Eric Halioua CHM	Chairman	-	01/09/2025
Virginie Miath BRD	Director/Board Member	-	29/01/2026

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-2.33%	-2.09%	+49.88%	+169.76%	1,060B
JOHNSON & JOHNSON	-0.82%	-2.30%	+63.79%	+62.56%	619B
ABBVIE INC.	-0.73%	-4.98%	+28.91%	+83.79%	438B
ROCHE HOLDING AG	-0.15%	+1.45%	+30.62%	+25.78%	333B
NOVARTIS AG	+0.10%	-0.56%	+29.01%	+47.04%	282B
ASTRAZENECA PLC	-1.32%	-10.17%	+18.80%	+22.61%	267B
NOVO NORDISK A/S	+0.05%	+0.79%	-26.98%	-38.10%	218B
AMGEN INC.	-0.06%	-2.88%	+23.07%	+61.02%	196B
GILEAD SCIENCES, INC.	-3.72%	-1.10%	+18.41%	+69.98%	161B
Average	+0.10%	-3.33%	+26.17%	+56.05%	397.1B
Weighted average by Cap.	+0.02%	-3.10%	+36.37%	+83.43%

	2023	2024
Net sales	336K 384K 384K 310K 286K 543K 36.64M 552K 3.7M 1.45M 18.05M 1.44M 1.41M 62.05M	102K 117K 117K 94.08K 86.89K 165K 11.12M 168K 1.12M 441K 5.48M 438K 428K 18.84M
Net income	-28.78M -32.9M -32.9M -26.54M -24.52M -46.52M -3.14B -47.3M -317M -125M -1.55B -124M -121M -5.31B	-4.77M -5.45M -5.45M -4.4M -4.06M -7.71M -520M -7.84M -52.55M -20.64M -256M -20.47M -20.02M -880M
Net Debt	28.04M 32.06M 32.06M 25.86M 23.89M 45.33M 3.06B 46.09M 309M 121M 1.51B 120M 118M 5.18B	27.34M 31.25M 31.25M 25.21M 23.29M 44.19M 2.98B 44.93M 301M 118M 1.47B 117M 115M 5.05B

End-of-day quote Euronext Bruxelles Other stock markets
-	-